Liquidia Corp
NASDAQ:LQDA
Liquidia Corp
Income from Continuing Operations
Liquidia Corp
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Liquidia Corp
NASDAQ:LQDA
|
Income from Continuing Operations
-$130.4m
|
CAGR 3-Years
-56%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Income from Continuing Operations
$14.1B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-1%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Income from Continuing Operations
-$8.9B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Pfizer Inc
NYSE:PFE
|
Income from Continuing Operations
$8.1B
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-1%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Income from Continuing Operations
$17.1B
|
CAGR 3-Years
12%
|
CAGR 5-Years
25%
|
CAGR 10-Years
4%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Income from Continuing Operations
$10.6B
|
CAGR 3-Years
24%
|
CAGR 5-Years
18%
|
CAGR 10-Years
16%
|
|
Liquidia Corp
Glance View
Liquidia Corp. operates as a holding company which through its subsidiary engages in developing and commercializing biopharmaceutical products. The company is headquartered in Morrisville, North Carolina and currently employs 47 full-time employees. The company went IPO on 2018-07-26. PRINT technology is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. The firm is engaged in developing product candidates from its pipeline, LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. LIQ861 is an inhaled dry powder formulation of treprostinil designed to improve the therapeutic profile of treprostinil by enhancing deep-lung delivery and achieving higher dose levels than current inhaled therapies. LIQ865, has completed a Phase Ib clinical trial, is designed to deliver sustained-release particles of bupivacaine, a non-opioid anesthetic and to treat local post-operative pain.
See Also
What is Liquidia Corp's Income from Continuing Operations?
Income from Continuing Operations
-130.4m
USD
Based on the financial report for Dec 31, 2024, Liquidia Corp's Income from Continuing Operations amounts to -130.4m USD.
What is Liquidia Corp's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-22%
Over the last year, the Income from Continuing Operations growth was -66%. The average annual Income from Continuing Operations growth rates for Liquidia Corp have been -56% over the past three years , -22% over the past five years .
You don't have any saved screeners yet